Details of the Drug

General Information of Drug (ID: DMXCM7H)

Drug Name

Cerivastatin

Synonyms

cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins

Indication

Disease Entry	ICD 11	Status	REF
Hyperlipidaemia	5C80	Approved	[1]
Multiple myeloma	2A83	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

459.5

Logarithm of the Partition Coefficient (xlogp)

3.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 60% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.9 mL/min/kg [4]
Elimination: 24% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.01088 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.33 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 195 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Rhabdomyolysis	rs2819742	RYR2	OT0PF19E	[6]
-----------

Chemical Identifiers

Formula: C26H34FNO5
IUPAC Name: (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
Canonical SMILES: CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
InChI: InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
InChIKey: SEERZIQQUAZTOL-ANMDKAQQSA-N

Cross-matching ID

PubChem CID: 446156
ChEBI ID: CHEBI:3558
CAS Number: 145599-86-6
DrugBank ID: DB00439
TTD ID: D03KIA
VARIDT ID: DR00391
INTEDE ID: DR0290

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium/taurocholate cotransporting polypeptide (SLC10A1)	DT56EKP	NTCP_HUMAN	Substrate	[7]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[8]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[9]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[10]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[11]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[13]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[14]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[15]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Ryanodine receptor 2 (RYR2)	OT0PF19E	RYR2_HUMAN	Drug Response	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

02 Neoplasm

Disease Class

ICD-11: 2C82 Prostate cancer

The Studied Tissue

Bone marrow

The Studied Disease

Multiple myeloma [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
HMG-CoA reductase (HMGCR)	DTT	HMGCR	1.48E-06	1.01	4.34
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.42E-01	-4.36E-02	-2.21E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.80E-01	2.46E-01	2.41E-01
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTP	OATP2B1	1.70E-02	-1.23E+00	-1.37E+00
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTP	OATP2B1	4.78E-01	9.86E-02	7.44E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	3.08E-02	-4.06E-01	-8.83E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	7.10E-01	5.87E-03	1.61E-02
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	2.22E-01	-1.68E-01	-6.27E-01
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	2.44E-01	6.35E-02	3.90E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	2.19E-02	4.44E-02	4.09E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	6.12E-01	1.16E-01	7.74E-01
Sodium/taurocholate cotransporting polypeptide (SLC10A1)	DTP	NTCP	1.21E-03	-4.83E-01	-2.00E+00
Sodium/taurocholate cotransporting polypeptide (SLC10A1)	DTP	NTCP	2.13E-01	1.57E-01	7.50E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	1.50E-04	1.94E-01	2.06E+00
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	6.86E-01	3.72E-02	2.86E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	6.60E-01	2.51E-02	8.26E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	8.62E-03	1.37E-01	8.67E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	7.83E-01	2.87E-03	6.52E-02
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	5.86E-02	-1.69E-01	-8.79E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	2.26E-02	7.10E-02	1.00E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	7.23E-01	-2.28E-02	-3.11E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.51E-01	8.39E-02	5.00E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.93E-04	-6.16E-01	-2.64E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cerivastatin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[16]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Cerivastatin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[17]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Cerivastatin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[18]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Cerivastatin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[19]
-----------

Coadministration of a Drug Treating the Disease Different from Cerivastatin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Cerivastatin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[20]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[21]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Cerivastatin due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[21]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Cerivastatin caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[22]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Cerivastatin caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[22]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Cerivastatin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[23]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Cerivastatin caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[24]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Cerivastatin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[20]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Cerivastatin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Cerivastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Cerivastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[26]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Cerivastatin caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[27]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[20]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Cerivastatin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[28]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Cerivastatin caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Cerivastatin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Cerivastatin caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Cerivastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[25]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Cerivastatin caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[29]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[30]
MK-8228	DMOB58Q	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by MK-8228.	Cytomegaloviral disease [1D82]	[31]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Cerivastatin caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[22]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Cerivastatin caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Cerivastatin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[33]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Cerivastatin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Cerivastatin caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Cerivastatin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[24]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Cerivastatin caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[21]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Cerivastatin caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[24]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Cerivastatin caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[22]
Simeprevir	DMLUA9D	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[34]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Tipranavir	DM8HJX6	Major	Decreased metabolism of Cerivastatin caused by Tipranavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Cerivastatin caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Saquinavir	DMG814N	Major	Decreased metabolism of Cerivastatin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Cerivastatin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Cerivastatin and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Cerivastatin caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Darunavir	DMN3GCH	Major	Decreased metabolism of Cerivastatin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Cerivastatin caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Ritonavir	DMU764S	Major	Decreased metabolism of Cerivastatin caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Cerivastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[22]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Cerivastatin caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[22]
Conivaptan	DM1V329	Major	Decreased metabolism of Cerivastatin caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[41]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Cerivastatin caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[22]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Cerivastatin and Methotrexate.	Leukaemia [2A60-2B33]	[21]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Cerivastatin caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[22]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Cerivastatin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Cerivastatin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[43]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Cerivastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Cerivastatin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[44]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Cerivastatin and Clofarabine.	Mature B-cell lymphoma [2A85]	[45]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Cerivastatin caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[20]
Danazol	DML8KTN	Major	Decreased metabolism of Cerivastatin caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[25]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Cerivastatin caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[46]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Cerivastatin and Thalidomide.	Multiple myeloma [2A83]	[39]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Cerivastatin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Cerivastatin caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Cerivastatin caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Cerivastatin caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Modafinil	DMYILBE	Minor	Increased metabolism of Cerivastatin caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[47]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Cerivastatin caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[25]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Cerivastatin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[22]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Cerivastatin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Cerivastatin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[49]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Cerivastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[50]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Cerivastatin caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[18]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Cerivastatin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[51]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[21]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Cerivastatin and Leflunomide.	Rheumatoid arthritis [FA20]	[18]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Cerivastatin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[25]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Cerivastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[21]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Cerivastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
Armodafinil	DMGB035	Minor	Increased metabolism of Cerivastatin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[47]
Epirubicin	DMPDW6T	Moderate	Increased risk of hepatotoxicity by the combination of Cerivastatin and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Cerivastatin and Naltrexone.	Substance abuse [6C40]	[52]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Cerivastatin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[53]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Cerivastatin caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[22]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Cerivastatin and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[54]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Cerivastatin and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[54]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Cerivastatin caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[22]
-----------


⏷ Show the Full List of 82 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2950).
2	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
7	Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
8	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
9	pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
10	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11	FDA Drug Development and Drug Interactions
12	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
14	Drug Interactions Flockhart Table
15	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
16	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
17	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
18	Canadian Pharmacists Association.
19	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
20	Cerner Multum, Inc. "Australian Product Information.".
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
23	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
24	Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
25	Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
26	Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9. [PMID: 11936570]
27	East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988): 47-8. [PMID: 3275892]
28	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
29	Cerner Multum, Inc. "Canadian Product Information.".
30	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
31	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
32	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
33	Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
34	Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74. [PMID: 18563955]
35	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
36	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
37	Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
38	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
39	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
40	Cheng CH, Miller C, Lowe C, Pearson VE "Rhabdomyolysis due to probable interaction between simvastatin and ritonavir." Am J Health Syst Pharm 59 (2002): 728-30. [PMID: 11977859]
41	Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
42	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
43	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
45	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
46	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
47	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
48	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
51	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
52	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
53	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
54	Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]